Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 De?ciency Disorder
Viralgen ha annunciato una collaborazione con Elaaj Bio per sviluppare una terapia genica destinata a un raro disturbo neurologico infantile. La partnership si concentra sulla produzione di vettori AAV, utilizzati in una fase preclinica per un trattamento della delezione del gene CDKL5. Questa iniziativa mira a portare avanti il progetto di terapia genica attraverso competenze specializzate nella produzione di vettori virali.
COMUNICATO STAMPA – CONTENUTO PROMOZIONALE Collaboration leverages AAV manufacturing expertise to advance a preclinical-stage gene therapy program for a rare pediatric neurological disorder. SAN SEBASTIÁN, Spain and LONDON, May 5, 2026 PRNewswire — Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development of transformative treatments for CDKL5 De?ciency Disorder (CDD). Elaaj Bio is a wholly owned subsidiary of the Loulou Foundation, a private non-pro?t foundation dedicated to the development and research of therapeutics for CDD.🔗 Leggi su Corrieretoscano.it
Notizie correlate
Leggi anche: La nutrizionista risponde. Binge eating disorder: cos’è, i sintomi e come uscirne
Applied Intuition Collaborates with Heidelberg Materials to Advance Innovation in Quarry Operations with Autonomous Haulage FleetsCOMUNICATO STAMPA – CONTENUTO PROMOZIONALE Deployment brings intelligent, vehicle-based autonomy to Australia, establishing a new operating model for...
➜